SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-20-014567
Filing Date
2020-12-30
Accepted
2020-12-30 07:10:40
Documents
15
Period of Report
2020-12-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20201230x8k.htm   iXBRL 8-K 39988
2 EX-99.1 plx-20201230xex99d1.htm EX-99.1 12308
3 GRAPHIC plx-20201230xex99d1002.jpg GRAPHIC 1661
4 GRAPHIC plx-20201230xex99d1001.jpg GRAPHIC 5207
  Complete submission text file 0001558370-20-014567.txt   190072

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20201230.xsd EX-101.SCH 3250
6 EX-101.LAB plx-20201230_lab.xml EX-101.LAB 16114
7 EX-101.PRE plx-20201230_pre.xml EX-101.PRE 10898
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20201230x8k_htm.xml XML 4912
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 201424004
SIC: 2836 Biological Products, (No Diagnostic Substances)